Asparkam AVEKSIMA - instructions for use, dose, side effects, contraindications

Asparta is a source of potassium and magnesium ions, regulates metabolic processes. The mechanism of action is presumably associated with the role of aspartate as a carrier of magnesium and potassium ions in the intracellular space and with the participation of aspartate in metabolic processes. Thus, Asparkam eliminates the imbalance of electrolytes, reduces the excitability and conductivity of the myocardium (moderate antiarrhythmic effect).

Pharmacokinetics:Easily absorbed when ingested and relatively quickly excreted by the kidneys.

Indications:

Asparks are used in the complex therapy of chronic heart failure, ischemic heart disease, hypokalemia, cardiac rhythm disturbances (including myocardial infarction, cardiac glycoside overdose).

Contraindications:

Hypersensitivity to the drug, impaired metabolism of amino acids, acute and chronic renal failure, hyperkalemia, hypermagnesia, insufficiency of the adrenal cortex, violation of atrioventricular conduction (AV blockade I-III ), severe myasthenia gravis, hemolysis, arterial hypotension (systolic blood pressure less than 90 mm Hg), age to 18 years.

Pregnancy and lactation:Carefully.

Dosing and Administration:

Assign inside after eating. Adults take 1-2 tablets 3 times a day. The course of treatment is 3-4 weeks. If necessary, repeat the course.

Side effects:

Possible nausea, vomiting, diarrhea, discomfort or burning sensation in the pancreas (in patients with an anatomic gastritis or cholecystitis), atrioventricular blockade, paradoxical reaction (increase in the number of extrasystoles),hyperkalemia (nausea, vomiting, diarrhea, parasthesia), hypermagnesia (redness of the face, thirst, lowering of blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions).

Overdose:

Symptoms: hyperkalemia, hypermagnesia.

Treatment: in / in calcium chloride, if necessary - hemodialysis and peritoneal dialysis.

Interaction:

Pharmacodynamic: joint application with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin converting enzyme inhibitors, non-steroidal anti-inflammatory drugs increases the risk of hyperkalemia up to the development of arrhythmia and asystole. The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter. Due to the content of potassium ions, the undesirable effects of cardiac glycosides decrease. Due to the content of magnesium ions reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin. May enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracurium bezylate, decamethonium bromide, suxamethonium (chloride, bromide, iodide). Calcitriol increases the concentration of magnesium ions in the blood plasma, calcium preparations reduce the effect of magnesium.

Pharmacokinetic: astringent and enveloping agents reduce the absorption of the drug in the gastrointestinal tract (a 3-hour interval between their intake must be observed).

Special instructions:It is necessary to control the content of potassium ions in the blood plasma.

Effect on the ability to drive transp. cf. and fur:

Clinical studies to assess the effect of the drug on the ability to manage vehicles and mechanisms have not been conducted.

Form release / dosage:

Pills.

Packaging:

For 8, 10 or 12 tablets in a contour mesh package.

For 10 tablets in a contour non-jawed package.

50 tablets per can of polymeric materials.

By 6 or 7 contour cell packs on 8 tablets, on 5 contour cellular Packs of 10 tablets, 4 or 5 contour cell packs for 12 tablets or 1 can of polymeric materials together with instructions for medical use are placed in a pack of cardboard. Contour non-cellular packages with an equal number of instructions for medical use or a pack of cardboard are placed in a group package.

Storage conditions:

Keep at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:3 years. After expiration date the drug should not be used.

Terms of leave from pharmacies:On prescription

Registration number:LSR-005781/10

Date of registration:23.06.2010 / 20.05.2016

Expiration Date:Unlimited

The owner of the registration certificate:AVEKSIMA, JSC AVEKSIMA, JSC Russia

Manufacturer: & nbsp

IRBITSK HFZ, OJSC Russia

Information update date: & nbsp27.09.2017

Illustrated instructions

Instructions

ASPEKARA AVEKSIMA (ASPARCAM AVEKSIMA)